Study Summary
This study aims to evaluate the safety, efficacy and duration of response of CD22 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in patients with high risk, relapsed CD22+ haematological malignancies.
Interested in this trial?
Submit an InquiryInterventions
:Anti-CD22-CARBIOLOGICAL
Cells extracted, followed by induction chemotherapy before CD22-CAR infusion (dose escalation.)
Study Locations
No locations listed.